Chronopharmacokinetic and Metabolite Studies of the Cardiovascular Medication Sacubitril

Abstract

People with “heart failure with preserved ejection fraction” have heart failure, but their ejection fraction is still pretty normal (HFpEF). When it comes to heart failure, people with normal or nearly normal ejection fractions are more likely to get it than those with lower ejection fractions. In clinical trials with HFpEF, medications such as angiotensin-converting enzyme inhibitors (ACEIs), aldosterone antagonists, beta-blockers, calcium channel blockers, and angiotensin receptor blockers (ARBs) did not yield any beneficial results. Sacubitril is prescribed to peritoneal dialysis patients with end-stage renal disease in order to manage their hypertension and heart failure. The concentrations of sacubitril and its primary metabolite in plasma, urine, and peritoneal dialysis fluid were determined using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). This method is effective because it doesn’t take much time but produces good results. Several samples of body fluids were taken with the help of protein precipitation. The positive ion mode of ionization from the UPLC-MS/electrospray MS was used to look at the extracts. With correlation values of 0.99991 for sacubitril, the suggested method was carefully tested. With this method, it is possible to find out exactly how much sacubitril are in plasma, urine, and peritoneal dialysis fluid. It is also honest, dependable, and nice. If the experiment works, we’ll know that peritoneal dialysis changed how sacubitril were cleared from the body.